Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) and SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.
Volatility and Risk
Avalo Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.
Earnings & Valuation
This table compares Avalo Therapeutics and SAB Biotherapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avalo Therapeutics | $60,000.00 | 13,827.60 | -$78.26 million | ($4.37) | -3.54 |
| SAB Biotherapeutics | $1.32 million | 226.79 | $13.27 million | ($1.30) | -2.53 |
SAB Biotherapeutics has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Avalo Therapeutics and SAB Biotherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avalo Therapeutics | 1 | 0 | 12 | 0 | 2.85 |
| SAB Biotherapeutics | 1 | 1 | 9 | 0 | 2.73 |
Avalo Therapeutics presently has a consensus price target of $45.10, suggesting a potential upside of 191.53%. SAB Biotherapeutics has a consensus price target of $12.00, suggesting a potential upside of 264.74%. Given SAB Biotherapeutics’ higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than Avalo Therapeutics.
Profitability
This table compares Avalo Therapeutics and SAB Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avalo Therapeutics | N/A | -58.03% | -48.22% |
| SAB Biotherapeutics | N/A | -6.74% | -6.06% |
Summary
SAB Biotherapeutics beats Avalo Therapeutics on 8 of the 13 factors compared between the two stocks.
About Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
